NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its progress toward completion of the clinical study plan required for its FDA 510(k) submission. In August 2024, INBS announced its partnership with CenExel to perform the method comparison study as part of the Company's clinical study plan. The study involves the recruitment of 135 h ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base. As of June 30, 2024, the estimated number of employees within INBS' global customer base has grown by 720,000 compared to an increase of 329,000 the fiscal year ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a leading innovator in non-invasive drug testing technology, today announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers as of June 30, 2024. This achievement marks a significant milestone for INBS, underscoring the growing demand for the Company's advanced drug screening technology. In the fiscal year ending June 30, 2024, the Company sold ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative, non-invasive drug testing technologies. The challenges faced across these critical sectors are: ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech ("Qabas") as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment to improving public safety. Qabas is a leading technology provider in Saudi Arabia with a st ...

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced QabasTech (“Qabas”) as its exclusive distributor in Saudi Arabia. This partnership marks further growth for INBS in the country, aligning with its ambitious infrastructure projects and commitment to improving public safety. Qabas is a leading technology provider in Saudi Arabia with a s ...

NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance. The biocompatibility study, conducted in accordance with ISO 10993 standards, involved a ...

NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of biocompatibility testing of its Intelligent Fingerprinting Drug Screening System, a pivotal phase in the clinical study plan required for FDA 510(k) regulatory clearance. The biocompatibility study, conducted in accordance with ISO 10993 standards, involved ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of several key accounts in the UK manufacturing sector. This announcement follows recent successes in the warehouse and logistics, transport and infrastructure, and retail sectors as the Company's growth momentum continues. Recent additions to INBS' customer account portfoli ...